Publisher Correction: Real-world effectiveness of CDK 4/6 inhibitors in estrogen-positive metastatic breast cancer

被引：0
|
作者：
Mathilde Louise Gehrchen [1 ]
Tobias Berg [1 ]
Rasmus Garly [2 ]
Maj-Britt Jensen [1 ]
Saskia Eßer-Naumann [1 ]
Jeanette Dupont Rønlev [3 ]
Hanne Melgaard Nielsen [4 ]
Ann Knoop [5 ]
Iben Kümler [1 ]
机构：
[1] Copenhagen University Hospital,Danish Breast Cancer Group, Department of Oncology
[2] Rigshospitalet,Department of Oncology
[3] Copenhagen University Hospital,Department of Oncology
[4] Rigshospitalet,Department of Oncology
[5] Næstved Hospital,Department of Oncology
[6] University Hospital of Odense,Department of Oncology
[7] Aarhus University Hospital,Department of Clinical Medicine, Faculty of Health and Medical Sciences
[8] Herlev and Gentofte University Hospital,undefined
[9] University of Copenhagen,undefined
来源：
BJC Reports | / 2卷 / 1期
关键词：
D O I：
10.1038/s44276-024-00083-5
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [31] Real-World Effectiveness of Palbociclib Plus Aromatase Inhibitors in African American Patients With Metastatic Breast Cancer
    Rugo, Hope S.
    Liu, Xianchen
    Li, Benjamin
    McRoy, Lynn
    Chen, Connie
    Layman, Rachel M.
    Brufsky, Adam
    ONCOLOGIST, 2023, 28 (10): : 866 - 874
  • [32] Palbociclib plus aromatase inhibitors in patients with metastatic breast cancer and cardiovascular diseases: real-world effectiveness
    Brufsky, Adam
    Liu, Xianchen
    Li, Benjamin
    McRoy, Lynn
    Chen, Connie
    Makari, Doris
    Layman, Rachel M.
    Rugo, Hope S.
    ONCOLOGIST, 2024, 29 (12): : 1032 - 1043
  • [33] Efficacy and safety of cyclin dependent kinases 4/6 inhibitors in the treatment of metastatic breast cancer: a real-world experience
    Kessler, Luisa Edman
    Wiklander, Oscar
    Hamberg, Eva
    Bergh, Jonas
    Foukakis, Theodoros
    Matikas, Alexios
    ACTA ONCOLOGICA, 2020, 59 (11) : 1382 - 1387
  • [34] Overcoming resistance to inhibitors of CDK4/6 and BET in estrogen receptor-positive breast cancer
    Cosin, Marc
    Tian, Tian
    Oliveros, Winona
    Kharenko, Olesya A.
    van der Horst, Edward H.
    Patel, Reena G.
    Calosing, Cyrus
    Campeau, Eric
    Jahagirdar, Ravi
    Lakhotia, Sanjay
    Mele, Marta
    Palafox, Marta
    Arribas, Joaquin
    Oliveira, Mafalda
    Saura, Cristina
    Serra, Violeta
    Peiro, Sandra
    CANCER RESEARCH, 2020, 80 (16)
  • [35] A Real-World Evidence Study of CDK4/6 Inhibitor Treatment Patterns and Outcomes in Metastatic Breast Cancer by Gbrcamutation Status
    Untch, Michael
    Fasching, Peter Andreas
    Mclaurin, Kimmie
    ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 : 11 - 11
  • [36] CDK4/6 inhibitors in HR+/HER2-advanced/metastatic breast cancer: a systematic literature review of real-world evidence studies
    Harbeck, Nadia
    Bartlett, Meaghan
    Spurden, Dean
    Hooper, Becky
    Zhan, Lin
    Rosta, Emily
    Cameron, Chris
    Mitra, Debanjali
    Zhou, Anna
    FUTURE ONCOLOGY, 2021, 17 (16) : 2107 - 2122
  • [37] Which are the clinicopathological characteristics useful to define the metastatic breast cancer patients that will respond to CDK4/6 inhibitors and hormone therapy? An Italian real-world experience
    Bravaccini, Sara
    Roncadori, Andrea
    Balzi, William
    Martinelli, Giovanni
    Montella, Maria Teresa
    Palleschi, Michela
    Maltoni, Roberta
    CANCER RESEARCH, 2023, 83 (07)
  • [38] Adverse kidney outcomes of CDK 4/6 inhibitors for metastatic breast cancer
    Hanna, Paul E.
    Strohbehn, Ian A.
    Moreno, Daiana
    Harden, Destiny
    Seethapathy, Rituvanthikaa
    Sawtell, Rani
    Wang, Qiyu
    Ouyang, Tianqi
    Katz-Agranov, Nurit
    Dinulos, James
    Wander, Seth A.
    Gupta, Shruti
    Sise, Meghan E.
    NPJ BREAST CANCER, 2023, 9 (01)
  • [39] Real-world hematologic toxicities in patients > 70 versus < 69 with ER positive metastatic breast cancer on CDK 4/6 inhibitors: Single-institution retrospective study.
    Olazagasti, Coral
    Liu, Wingsze
    Lee, Chung-Shien
    Decina, Taylor
    Pappas, Karalyn
    Cheng, Kit
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [40] Adverse kidney outcomes of CDK 4/6 inhibitors for metastatic breast cancer
    Paul E. Hanna
    Ian A. Strohbehn
    Daiana Moreno
    Destiny Harden
    Rituvanthikaa Seethapathy
    Rani Sawtell
    Qiyu Wang
    Tianqi Ouyang
    Nurit Katz-Agranov
    James Dinulos
    Seth A. Wander
    Shruti Gupta
    Meghan E. Sise
    npj Breast Cancer, 9
12345